Hematologic Oncology

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

John Kuruvilla, MD, FRCPC, discusses the pivotal KEYNOTE-204 findings in Hodgkin lymphoma and the future of checkpoint inhibitors.

The European Medicines Agency has validated and accepted a marketing authorization application for zanubrutinib for the treatment of patients with Waldenström macroglobulinemia who have received at least 1 prior therapy or as frontline treatment for patients who are ineligible for chemoimmunotherapy.

Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.

Sarah Rutherford, MD, discusses the importance of including patients with double-hit lymphoma in clinical trials.

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

A new drug application has been completed and submitted to the FDA for the accelerated approval of umbralisib as a treatment for patients with previously treated MZL and follicular lymphoma.

Naveen Pemmaraju, MD, discusses what the early data with eprenetapopt in combination with azacitidine could mean for the future in MDS and AML.

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend caplacizumab-yhdp (Cablivi) for use with plasma exchange and immunosuppression in the treatment of acute episodes of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

The US Food and Drug Administration has extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.

More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.

The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.